Catalyst
Slingshot members are tracking this event:
Acadia's (ACAD) Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis Stopped Early for Positive Efficacy
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ACAD |
|
|
Additional Information
Upon the recommendation of the study’s independent data monitoring committee, which met to review the data from the planned interim efficacy analysis, the study will now be stopped early based on pre-specified stopping criteria requiring a one-sided p-value less than 0.0033 on the study’s primary endpoint.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 09, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pimavanserin, Dementia, Psychosis, Harmony Study